Measure Title: RELATING TO TERMINAL ILLNESSES.
Report Title: Terminal Illness; Investigative Drug or Biological Product; Access to Care; Right-to-Try
Description: Authorizes manufacturers of investigational drugs or biological products that are pending approval by the United States Food and Drug Administration to make the drugs or products available to terminally ill patients under certain conditions. Effective 12/31/2050. (SD1)
Companion:
Package: None
Current Referral: HHS, CPN/JDC
Introducer(s): CHANG, FEVELLA, MCKELVEY
Act:

Sort by DateChamberStatus Text
2/7/2025SReport adopted; Passed Second Reading, as amended (SD 1) and referred to CPN/JDC.
2/7/2025SReported from HHS (Stand. Com. Rep. No. 90) with recommendation of passage on Second Reading, as amended (SD 1) and referral to CPN/JDC.
1/29/2025SThe committee(s) on HHS recommend(s) that the measure be PASSED, WITH AMENDMENTS. The votes in HHS were as follows: 5 Aye(s): Senator(s) San Buenaventura, Aquino, Hashimoto, Keohokalole, Fevella; Aye(s) with reservations: none ; 0 No(es): none; and 0 Excused: none.
1/24/2025SThe committee(s) on HHS has scheduled a public hearing on 01-29-25 1:00PM; Conference Room 225 & Videoconference.
1/16/2025SReferred to HHS, CPN/JDC.
1/15/2025SIntroduced and passed First Reading.
1/8/2025SPending Introduction.

S = Senate | H = House | D = Data Systems | $ = Appropriation measure | ConAm = Constitutional Amendment

Some of the above items require Adobe Acrobat Reader. Please visit Adobe's download page for detailed instructions.


SB49 SD1

All Versions of this Measure

SB49_SD1 Link to SB49_SD1 .PDF file
SB49 Link to SB49 .PDF file

Committee Reports

SB49_SD1_SSCR90_ Link to committee report SB49_SD1_SSCR90_ .PDF file

Testimony

SB49_TESTIMONY_HHS_01-29-25_

Hearing Notices

HHS
1/29/25 1:00P
CR 225 & Videoconference